Experienced in Hemorrhagic Proctocolitis

Simona M. Bataga

Targu-mures, MS, RO 
Experienced in Hemorrhagic Proctocolitis
Targu-mures, MS, RO 
OverviewLocationsClinical Research

Overview

Simona Bataga practices in Targu-mures, Romania. Ms. Bataga is rated as an Experienced expert by MediFind in the treatment of Hemorrhagic Proctocolitis. Her top areas of expertise are Helicobacter Pylori Infection, Peptic Ulcer, Gastroesophageal Reflux Disease (GERD), Hepatitis C, and Endoscopy.

Her clinical research consists of co-authoring 26 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article and participated in 3 clinical trials in the study of Hemorrhagic Proctocolitis.

Gender
Female

Locations

Targu-mures, MS 540139, Romania
Other Locations
Constanta, CT, Romania
MS, Romania

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
Enrollment Status: Active_not_recruiting
Publish Date: October 10, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
View 2 Less Clinical Trials

26 Total Publications

Fecal Zonulin as a Non-Invasive Marker of Intestinal Permeability: Findings from a Prospective Cohort Study.
Fecal Zonulin as a Non-Invasive Marker of Intestinal Permeability: Findings from a Prospective Cohort Study.
Journal: Medicina (Kaunas, Lithuania)
Published: July 27, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Bataga's expertise for a condition
ConditionClose
        View All 16 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile